| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
20,130 |
19,418 |
$256K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
20,076 |
19,373 |
$253K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
3,452 |
3,179 |
$150K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
11,641 |
11,273 |
$112K |
| 87480 |
|
15,027 |
14,407 |
$107K |
| 87660 |
|
14,480 |
13,905 |
$102K |
| 87510 |
|
14,501 |
13,930 |
$92K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
7,522 |
7,245 |
$92K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
1,385 |
1,298 |
$58K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
1,701 |
1,654 |
$32K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
1,933 |
1,876 |
$28K |
| 88141 |
|
3,065 |
2,966 |
$27K |
| 87563 |
|
1,211 |
1,195 |
$20K |
| 87625 |
|
758 |
713 |
$11K |
| 88142 |
|
835 |
803 |
$7K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
17 |
14 |
$107.96 |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
68 |
66 |
$0.00 |